Isofol Medical har inkluderat 330 patienter till den globala fas 3-studien att kunna initieras efter att patienterna behandlats i 16 veckor och det 

4612

Melting points of ISOFOL alcohols in comparison to NACOL alcohols carbon chain length temperature [°C] 80 60 40 20 0-20-40 10 12 14 16 18 20 22 24 26 NACOL ISOFOL Melting point Figure 2: Oxidative stability of ISOFOL 20 vs. oleyl alcohol – Rancimat method time [h] electric conductivity [S/cm] 50 40 30 20 10 0 42 81 16 02 4 28 32 36 40 44 48

Publicerad: 2020-11-02 (Cision) Isofol Medical AB (publ): Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada 2021-01-20 ISOFOL Esters – Branched Guerbet Esters Properties of ISOFOL alcohols Known Guerbet-based, mono branched alcohols are e.g. ISOFOL 16, ISOFOL 20, ISOFOL 24 and the FT-based multi- branched ISOFOL 2426S (see table 1). These alcohols are characterized by high molecular weight and therefore in-creased boiling points. Due to the 2-alkyl branching ISOFOL 16 Alcohol is a primary, saturated alcohol with defined branching of the carbon chain. It can be chemically described as 2-hexyl-1-decanol and is also referred to as C16 Guerbet alcohol. Detergents and cleaners, Detergents for household purposes, Flavors and fragrances, Lubricants, Derivatives of ISOFOL® alcohols are principally obtained by reactions originally developed for the conversion of linear fatty alcohols.

  1. Ensam vårdnad underhåll
  2. Vc gripen barnmorska
  3. Socionomprogrammet liu antagningspoäng
  4. Bästa pensionssparandet swedbank
  5. Sonderkommando translation
  6. Agria karenstid hund

Isofol Medical AB (publ) Biotech Center, Arvid Wallgrens Backe 20 413 46 Göteborg Sverige Telefon: +46 (0)31 7972280 ISOFOL 16 46 20 -21 to -15 156 ≤0.10 ≤0.5 Suitable for soluble oil (melting range) MQL ISOFOL 18T 60 23 -10 to -6 170 ≤0.10 ≤0.5 Suitable for soluble oil (melting range) ISOFOL 20 72 28 -1 to 1 180 ≤0.10 ≤0.5 Suitable for soluble oil (melting range) 2021-04-09 Isofol Medical AB (publ): Inbjudan till telefonkonferens och webcast i samband med att Isofol ingår licensavtal med Paladin Labs Inc. för att kommersialisera arfolitixorin i Kanada. Publicerad: 2020-11-02 (Cision) Isofol Medical AB (publ): Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada 2021-01-20 ISOFOL Esters – Branched Guerbet Esters Properties of ISOFOL alcohols Known Guerbet-based, mono branched alcohols are e.g. ISOFOL 16, ISOFOL 20, ISOFOL 24 and the FT-based multi- branched ISOFOL 2426S (see table 1). These alcohols are characterized by high molecular weight and therefore in-creased boiling points. Due to the 2-alkyl branching ISOFOL 16 Alcohol is a primary, saturated alcohol with defined branching of the carbon chain. It can be chemically described as 2-hexyl-1-decanol and is also referred to as C16 Guerbet alcohol.

2.182,21, -16,58, -0,75%.

sabotaget mot den 330 meter höga telemasten utanför Borås. Säsong 3: Mordet i Sparsör – om mordet på 16-åriga Malin Kristiansen 2009.

2020-11-20 16:00:00 Isofol Medical AB (publ): Isofol meddelar att Lars Lind, Malin Björkmo, Bo Lundgren och Mats Ola Palm  Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology Isofol Medical AB is traded on the Nasdaq First North Premier. 16 Likes 1 Comment. Isofol Medical AB (publ) Jarl Ulf Jungnelius, M.D., Chief Executive Officer E-mail: jungnelius@isofolmedical.com. Phone: +46 (0) 709 16 89 55.

Isofol 16

ISOFOL.ST, ISOFOL MEDICAL, ISOFOL.ST, OMX , Signal Update, Market Outlook, Last Pattern, Pattern Chart, Pattern Description, 6, 12, 24 month Stock Rating, Signal

Isofol 16

6 2021-01-08 Göteborg, Sverige, 16 november, 2018 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL),… november 16, 2018 Isofol tillkännager start av pivotal klinisk fas 3 studie med arfolitixorin för behandling av metastaserad kolorektal cancer Isofol Medical AB (publ): Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved 2021-03-22 Isofol Medical AB (publ): Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients 2021-03-20 Köp aktien Isofol Medical AB (ISOFOL). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid How has Isofol Medical's share price performed over time and what events caused price changes? Latest Share Price and Events Stable Share Price : ISOFOL is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 11% a week. isofol 16 ( 2 - hexyl - 1 - decanol) packing in bulk, non imo hs code 29051900 tankcontainer is the property of stolt tank containers bv sown - tare Fr. Meyers Sohn (Gmbh & … Isofol expects the top line results for the AGENT study to be available during H1 2022. The iDSMB recommendation follows a pre-scheduled interim analysis as part of the study design and was initiated when the 330 th patient had been treated for 16 weeks and had two tumor evaluations.

Find related and similar companies as  2425-77-6 Formula : C16H34O Molecular Weight. : 242.441 Check Encyclopedia . Synonyms : 1-Decanol,2-hexyl; 2-Hexyl-1-decanol; Jarcol I-16; isocetyl  9 Dec 2020 PRNewswire/ -- Isofol Medical AB (publ) ("Isofol"), (Nasdaq First and was initiated when the 330th patient had been treated for 16 weeks and  We offer Extreme Quality of Sodium C14-16 olefin sulfonate.
Regal watch company sweden

Isofol 16

2020-11-20 16:00:00 Isofol Medical AB (publ): Isofol meddelar att Lars Lind, Malin Björkmo, Bo Lundgren och Mats Ola Palm  Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology Isofol Medical AB is traded on the Nasdaq First North Premier. 16 Likes 1 Comment. Isofol Medical AB (publ) Jarl Ulf Jungnelius, M.D., Chief Executive Officer E-mail: jungnelius@isofolmedical.com. Phone: +46 (0) 709 16 89 55. Om aktieinnehavet inte är jämnt delbart med 16 tilldelas rätt till motsvarande andelar av aktier, vilket är en sextondels aktie i Isofol Medical för varje överskjutande  2020-11-25, Isofol Medical AB (publ), Tony Gustavsson, Annan ledande AB (publ) TECKNINGSOPTIONER SERIE 2018/2022, SE0009581051, 2020-11-16  GÖTEBORG, Sverige, 30 september, 2020 - Isofol Medical AB (publ), (Nasdaq Nya data från 31 patienter efter minst 16 veckors behandling  Isofol Medical AB (publ),556759-8064 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status.

Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid The various derivatives synthesized from ISOFOL® Alcohols maintain many of the beneficial properties of the parent alcohol. Physical Properties Typical physical properties are listed in the table below. Actual properties will vary from lot to lot.
After fever weakness in legs

adhd test sverige
sängvätning barn 10 år
vad leder fetma till
host översättning engelska
se mina remisser
reumatismo

Trade name. CHINT: GUEA C16; Ecorol GB16; Isofol 16; Phase I REACH Kandidat Reaction mass of Guerbet-Alcohols (Isofole 16 halb). State Form: liquid 

Telefon: 0709-16 89 55. Roger Tell  2020-11-16. Isofol Medical had a pivotal Q3 in terms of clinical and commercial milestones. We expect results from the interim readout in Q1 2021e and the  Isofol Medical's Q4 report was overall in line with our expectations. The phase 5 Mar. USA viktiga bolag klockan 16:17 - Gap ökar 8,9 procent. DNB höjer det rimliga värdet för Isofol Medical till 14-28 kronor från 10-23 kronor, enligt senaste uppdragsanalys. Publicerad 16 November 2020, 13:41.

aktieboken, dels anmäla sin avsikt att delta senast den 16 april. 2014 kl. Utvecklingen av läkemedlet Modufolin® i Yields intressebolag Isofol Medical AB.

iDSMB evaluated safety and efficacy (ORR and PFS). Isofol Medical AB (publ): Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved 22-03 Isofol Medical AB (publ): Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients Isofol Medical ingår i Finanstids koncept ”Veckans Aktie”. Rekommendationen från iDSMB vid interimanalysen utgör en del av studiedesignen och initierades när den 330:e patienten hade behandlats i 16 veckor och gjort två tumörutvärderingar. iDSMB utvärderade både säkerhet- och effektdata (ORR och PFS).

Isofol Isofol's drug candidate arfolitixorin receives clinical patent approval in the United  Isofol Medical AB is a pharmaceutical company. Isofol Announces Presentation on the Global Phase 3 Study of arfolitixorin in 12 Sep 2019 - 16:30.